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Self-emulsifying therapeutic system (SETs) provide an effective and intelligent solution to the various 
issues related to the formulation of hydrophobic drugs with limited solubility in gastrointestinal fluid. 
Although the potential utility of SETs is well known, only in recent years has a mechanistic understanding 
of the impact of these systems on drug disposition emerged. These in situ emulsion-forming systems 
have a high stability when incorporated in various dosage forms. SETs are being looked upon as 
systems which can overcome the problems associated with delivery of poorly water soluble drugs. 
An in-depth knowledge about lipids and surfactants that can contribute to these systems, criterion for 
their selection and the proportion in which they can be used, represent some crucial factors determining 
the in vivo performance of these systems. This article presents a comprehensive account of various 
types of self-emulsifying formulations with emphasis on their composition and examples of currently 
marketed preparations.
Uniterms: Lipid based formulations. Self-emulsifying therapeutic system. Self-emulsification.
O sistema terapêutico auto-emulsionante (SETs) fornece solução eficaz e inteligente para os vários 
problemas relativos à formulação de fármacos hidrofóbicos com solubilidade limitada no fluido 
gastrintestinal. Embora a utilidade potencial dos SETs seja bem conhecida, só recentemente  se 
compreendeu, mecanisticamente,o impacto desses sistemas na disposição de fármacos. Estes sistemas de 
formação de emulsão in situ têm alta estabilidade, quando incorporados em várias formas de dosagem. 
Os SETs têm sido considerados como sistemas que podem resolver problemas associados à liberação 
de fármacos pouco solúveis em água. O conhecimento profundo dos lipídios e tensoativos que podem 
ser utilizados para estes sistemas e o critério para a sua seleção e proporção na qual eles são utilizados 
são alguns dos fatores cruciais  que determinam o desempenho do sistema in vivo. Este artigo apresenta 
o relato abrangente de vários tipos de formulações auto-emulsificantes, com ênfase em sua composição 
e exemplos das preparações que são correntemente comercializadas. 
Unitermos: Formulações baseadas em lipídio. Sistema terapêutico auto-emulsificante. Auto-
emulsificação. 
INTRODUCTION
In the last decade, one of the major evolutions in the 
areas of pharmaceutics and drug delivery was the recog-
nition of benefits of formulating low water soluble actives 
as lipid based formulations, a process frequently referred 
to as a self-emulsifying therapeutic system. Low aqueous 
soluble compounds include a significant and increasing 
proportion of drug candidates, often viewed as high-risk 
drug candidates (Chong-Kook, Park, 2004; Giliyar et 
al., 2006; Fahr and Liu, 2007; Stegemann et al., 2007; 
Krishnaiah, 2010). The challenge lies in formulating these 
poorly-water soluble drug candidates. Extensive research 
is being carried out by formulation/drug delivery scientists 
to develop strategies to augment the solubility and deli-
very of biopharmaceutical classification system (BCS) 
class II and IV molecules (Benet et al., 2008; Dressman 
et al., 2001). Some approaches exploited to enhance drug 
solubility include preparation of solid dispersions (Sethia, 
Squillante, 2003; Leuner, Dressman, 2004), formulation 
of soft gelatin capsules (Gullapalli, 2010), cyclodex-
trin inclusion complexes (Stella, Qanren, 2008; Davis, 
Brewster, 2004), melt extrusion (Breitenbach, 2002), 
emulsions (Bittner, Mountfield, 2002), micro-emulsions 
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(Kawakami et al., 2002; Pouton, 2000), liposomes (Fenske 
et al., 2008; Malam et al., 2009) and micellar systems 
(Mohanty et al.,2010), in addition to the traditional metho-
ds such as use of co-solvents or salt/pro-drug formation. 
However, the lipid based formulation approach is consi-
dered a relatively newer strategy.
The value, utility and commercial viability of this 
approach for compounds with a low aqueous solubility has 
been demonstrated in recent years (Liversidge et al., 1995; 
Muller, 2001; Merisko-Liversidge et al., 2003; Pathak et 
al., 2005; Keck, Muller, 2006; Overhoff et al. 2007; Pu 
et al., 2009; Timpe, 2010). In addition, this approach has 
received significant attention, as reflected in the number 
of publications and reviews that have appeared recently 
(Hauss, 2007; Tang et al., 2008). A number of informative 
reviews have been published relating to biopharmaceuti-
cal aspects, strategies for formulation of self-emulsifying 
systems and efforts to understand their mechanisms of 
action (Humberstone, Charman, 1997; Constantinides, 
1995; Pouton, 1997; Gershanik, Benita, 2000). In practice, 
‘lipid’ formulations are a diverse group of formulations 
which have a wide range of properties.
The unique properties of lipids and their proven abi-
lity to formulate poorly-water soluble molecules may have 
a remarkable impact on enhancing bioavailability of drugs, 
eliminating food effects, allowing for dose escalation and 
thereby improving efficacy and safety. The present review 
is focused on the efforts that have been made in the field 
of self-emulsifying formulations for poorly water soluble 
drugs. Current developments in the design and develop-
ment of self-micro emulsifying and self-nano emulsifying 
formulations have also been highlighted.
NEED FOR LIPID BASED FORMULATIONS
During the last two decades, considerable efforts 
have been made in identifying biological targets of drug 
candidates. Also a number of lead molecules have been 
generated through combinatorial chemistry. With the avai-
lability of vast chemical libraries of new chemical entities, 
focus was set on designing molecules having high affinity 
binding constants for their biological targets. These biolo-
gical properties combined with appropriate physical and 
chemical properties could revolutionise drug development. 
However, poor aqueous solubility of drugs continues to 
remain a concern (Stegemann et al., 2007; Alsenz, Kansy, 
2007; Li, Zhao, 2007).
Generally, for a drug to show a high affinity and 
specificity for binding to molecular targets some degree 
of hydrophobic interactions is required where this hydro-
phobic interaction is likely to cause solubility constraints. 
While over 40% of molecules derived from combinatorial 
chemistry possess low aqueous solubility (Amidon, 2006; 
Lipinski, 2002; Lipinski, 2001) this percentage can reach 
~90% if the compound selection is not done cautiously. 
Only one out of approximately 5,000-10,000 new chemi-
cal entities (NCE) is successful as a drug candidate when 
there are no feasible means to deal with solubility issues. 
With an increasing number of poorly-water soluble NCE, 
it is necessary to evaluate and test these molecules to 
realize their genuine potential. The ability to use a drug 
delivery enabling technology for poorly-water soluble 
compounds could potentially have a tremendous impact 
on moving compounds successfully from discovery, 
through development and to the patient. In this context, 
application of lipid based formulations could be used 
for low aqueous soluble compounds and may ensure the 
success of the NCE.
“Lipid-based drug delivery systems” cover a wide 
array of formulation types, from oil solutions, emulsion 
and dry emulsions to Self-Emulsifying formulations 
(SEFs) as well as micellar systems. The absorption 
enhancing properties of lipid-based drug delivery syste-
ms are most often attributed to the ability of the vehicles 
to keep the API in solution in the gastrointestinal (GI) 
tract, thereby omitting the dissolution step. The absorp-
tion of the API will depend upon trafficking between 
different colloidal phases generated in the intestine. 
Lipid based drug delivery systems, and in particular 
self-emulsifying therapeutic systems (SETs), show great 
potential for enhancing oral bioavailability but have not 
been broadly applied, largely due to lack of general for-
mulation guidance. To help understand how formulation 
design influences physicochemical emulsion properties 
and associated function in the gastrointestinal environ-
ment, a number of studies carried out on self-emulsifying 
formulations have been discussed in the  sections that 
follow.
SELF-EMULSIFYING THERAPEUTIC SYSTEM 
(SETS)
SETs are pre-concentrates or anhydrous forms of 
emulsions. These systems are an anhydrous isotropic 
mixture of oils, surfactant(s) and drug, which when in-
troduced into the aqueous phase under gentle agitation, 
spontaneously form o/w emulsion (droplet size between 
100 and 300 nm) while self-micro emulsifying formula-
tions (SMEFs) form transparent micro-emulsions with 
a droplet size of less than 50 nm. Formulations based on 
SETs contain co-emulsifier or co-surfactant and/or solu-
bilizer in order to facilitate emulsification and improve 
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drug incorporation in SETs. Within the human body, the 
required agitation is provided by digestive motility of 
the GI tract (GIT).
SETs are usually formulated as simple emulsions 
or self-emulsifying formulations (SEFs) making use 
of surfactants with an HLB value of less than 12. Self-
micro-emulsifying formulations (SMEFs) and self-nano 
emulsifying formulations (SNEFs), on the other hand, are 
formulated using surfactants with an HLB value of more 
than 12. These formulations possess high stability and 
improved dissolution due to enhanced surface area upon 
dispersion. The comparative features of reported systems 
are illustrated in Figure 1.
Self-emulsification process
Self-emulsification takes place when the entropy 
change favours dispersion and is greater than the energy 
required to increase the surface area of the dispersion 
(Reiss, 1975). The free energy of a conventional emulsion 
formulation is a function of the energy required to create 
a new surface between the oil and water phases. The two 
phases of the emulsion tend to separate with time and 
reduce the interfacial area, and thus the free energy of the 
systems. The conventional emulsifying agents stabilize 
emulsions by forming a monolayer around the emulsion 
droplets, reducing the interfacial energy and forming a 
barrier to coalescence.
On the other hand, emulsification occurs sponta-
neously with SEFs because the free energy required to 
form the emulsion is low (Constantinides, 1995). For 
emulsification to occur, the interfacial structure must 
not show any resistance against surface shearing. The 
ease of emulsification is probably related to the ease of 
water penetration into the various liquid crystals or gel 
phases formed on the surface of the droplet (Groves et 
al., 1974; Wakerly et al., 1986; Rang, Miller, 1999). The 
interface between the oil and aqueous continuous phase 
is formed upon addition of a binary mixture consisting 
of oil and non-ionic surfactant in water. This is followed 
by the solubilisation of water within the oil phase as a 
result of aqueous penetration through the interface. This 
will continue until the solubilisation limit is reached. 
Further, aqueous penetration will lead to formation of 
the dispersed liquid crystals phase. Anything that is in 
close proximity with the interface will be in the form of 
liquid crystals and the actual amount of the liquid crystal 
will depend upon the concentration of surfactant in the 
binary mixture. Thus, following gentle agitation of the 
self-emulsifying system, water will rapidly penetrate 
into the aqueous cores and lead to interface disruption 
and droplet formation.
FIGURE 1. Features of different self-emulsifying formulations.
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Formulation considerations and potential 
components
A thorough understanding of the spontaneous 
emulsification process, the physiochemical and biological 
properties of components used for fabrication of SETs, is 
essential for formulation of effective SETs. Factors in-
fluencing the phenomenon of self-emulsification include:
·	 The physiological nature and concentration of 
oily phase, surfactant, co-emulsifier or co-surfactant and 
solubilizer;
·	 The ratio of each component, especially oil to 
surfactant ratio;
·	 The temperature and pH of the aqueous phase 
where emulsification would occur;
·	 Physicochemical properties of the drug, such as 
hydrophilicity/ lipophilicity, pKa and polarity.
Acceptability of SEFs components for the desired 
route of administration is important while formulating 
SEFs. Only specific pharmaceutical excipient combina-
tions lead to efficient self-emulsifying systems (Charman 
et al., 1992; Shah et al., 1994; Hauss et al., 1998; Karim 
et al., 1994). The components of SEFs which need consi-
dering are discussed below.
Oil phase
Oil phase has great importance while formulating 
SEFs, as the physicochemical properties of the oil (e.g. 
molecular volume, polarity and viscosity) significantly 
affect the spontaneity of the emulsification process, 
the droplet size of emulsion (o/w), drug solubility and 
biological fate of both the emulsion and drug. Oil phase 
represents one of the most important excipients in SEFs 
as it solubilizes the lipophilic drug, facilitates self-emul-
sification, and increases the fraction of lipophilic drug 
transported through the intestinal lymphatic system. This 
in turn increases the absorption from the GIT. However, 
the absorption is dependent upon the molecular nature of 
the triglyceride (Gershanik and Benita, 2000; Charman, 
1991; Holm et al., 2002).
Oils with medium hydrocarbon chain length (me-
dium chain triglycerides) and oils with short chains (or 
low molecular weight), such as medium chain triglyce-
rides and fatty acid esters (e.g. ethyl oleate), are easy to 
emulsify as compared with long chain triglycerides (An-
tron, Vandamme, 2009). Novel semi-synthetic medium 
chain derivatives, which can be defined as amphiphilic 
compounds with surfactant properties, are progressively 
replacing the regular medium chain triglyceride oils in the 
SEFs (Constantinides, 1995; Karim et al., 1994). 
It is difficult for a single oil component to have op-
timum properties with respect to emulsification and drug 
delivery. In certain cases, using a mixture of oils can also 
be used to attain optimum properties of the oily phase. 
Vitamin E (D-α- tocopherol) is increasingly being used 
as an oily phase in SEFs owing to its ability to solubilize 
drugs that are difficult to solubilize using conventional 
oil components, for example paclitaxel, itroconazole and 
saquinavir (Constantinides et al., 2004).
Surfactants
The choice of surfactant is critical for the formulation 
of SEFs. The properties of surfactants such as HLB value, 
cloud point, viscosity and affinity for oil phase, all have a 
strong influence on the emulsification process and droplet 
size. There is a direct relationship between the droplet size 
and concentration of surfactant being used. Increasing the 
surfactant concentration may lead to droplets with smaller 
mean droplet size. This could be explained by the stabiliza-
tion of the oil droplets as a result of the localization of the 
surfactant molecules at the oil-water interface (Karim et al., 
1994). On the other hand, in a few cases the mean droplet 
size was found to increase with greater surfactant concen-
trations (Georgakopoulos et al., 1992). This phenomenon 
could be attributed to the interfacial disruption elicited by 
enhanced water penetration into the oil droplets mediated 
by increased surfactant concentration, leading to ejection 
of oil droplets into the aqueous phase.
Surfactants used in these formulations improve the 
bioavailability of the drug. This can be attributed to diffe-
rent mechanisms including improved drug dissolution, 
increased intestinal epithelial permeability, increased tight 
junction permeability and inhibited P-glycoprotein drug 
efflux. However, a large quantity of surfactant may cause 
moderate reversible changes in intestinal wall permea-
bility or may irritate the gastrointestinal tract. However, 
formulation effect and effect of surfactant concentration 
on GIT mucosa should ideally be investigated in each case.
Several compounds exhibiting surfactant properties 
may be employed for the formulation of self-emulsifying 
systems. However, the list of such surfactants is limited. 
The most widely recommended non-ionic surfactants such 
as polysorbates (e.g., Tween® 80) and polyethylene glycol 
derivatives (e.g., Cremophor® EL) possess HLB in the 2 
to 18 range. These may be used in combination with lipid 
excipients to promote self-emulsification or micro-emulsi-
fication (Gibson, 2007). High HLB value and hydrophilicity 
are desirable characteristics of the surfactants for an imme-
diate formation of o/w droplets and rapid spreading of the 
formulation in the aqueous environment. The acceptable 
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amount of these otherwise low toxicity surfactants that can 
be used in the formulation of dosage forms is limited. This 
is primarily due to the tendency of these surfactants to cause 
brittleness in hard and soft gelatin capsule shells due to their 
dehydrating effects (at high concentrations).
Emulsifiers of natural origin are preferred in these 
formulations as they are considered safer than synthetic 
surfactants. Galactolipids, the polar lipids commonly 
found in the chloroplast membranes of green plants have 
been used as a surfactant in the formulation of cyclospori-
ne (Odeberg et al., 2003). However, surfactants of natural 
origin usually have a limited self-emulsification capacity 
(Gursoy et al., 2004).
Digestion of surfactants has been found to have 
an impact on the performance of SEFs. This is because 
the digestion of surfactant can change the solubilisation 
environment of the drug, which in-turn can causes precipi-
tation of the poorly water-soluble drugs (Cui et al., 2009; 
Fernandez et al., 2009). In addition, very little is known 
about the formation of degradation products of surfactants 
and their interactions with fatty acids, endogenous lipids 
(bile salts), phospholipids and dietary lipids. These factors 
may play a significant role in maintaining the solubility 
of poorly water-soluble drug in solution and the requisite 
building of mixed micelles might be compromised (Fer-
nandez et al., 2009).
Taking into account all these findings makes it 
apparent that knowledge of possible inhibitory effects of 
non-ionic surfactants on triglyceride digestion is crucial 
for the rational development of SEFs. Moreover, the sus-
ceptibility of the surfactants themselves to degradation 
by pancreatic enzymes is a crucial factor to be considered 
during formulation development.
Co-solvents
Usually an effective SEF requires a high concen-
tration of surfactant. Accordingly, co-solvents such as 
ethanol, propylene glycol and polyethylene glycol are 
required to facilitate the dissolution of large quantities of 
hydrophilic surfactant. These co-solvents sometimes play 
the role of the cosurfactant in the microemulsion system. 
On the other hand, alcohol and other volatile co-solvents 
have the drawback of evaporating into the shell of soft or 
hard gelatin capsules, leading to precipitation of the drug.
Aqueous phase
The droplet size and stability of W/O emulsion is 
influenced by the nature of aqueous phase where SETs is 
designed to be introduced. Hence, the pH and ionic content 
of aqueous phase is of prime importance when designing 
SETs. The physiological milieu has a diverse pH range 
varying from a pH of 1.2 (stomach) to around 7.4 (blood 
and intestine). In addition, the presence of various ions 
in the physiological milieu can also have a considerable 
effect on the properties of emulsions generated from SETs. 
The presence of electrolytes has been found to have an 
impact on emulsion characteristics such as droplet size and 
physical stability (Morais et al., 2006). Hence, it is advi-
sable to evaluate the self-emulsification of the SETs and 
the characteristics of resultant w/o emulsion in aqueous 
phases with varying pH and electrolyte concentration 
(depending upon the type of application). In addition to 
plain water, ringer’s solution, simulated gastric fluid (pH 
1.2), simulated intestinal fluid (pH 6.8) and phosphate 
buffer saline can be used as aqueous phase to evaluate 
spontaneous emulsification of SETs. In one study, pH of 
the aqueous phase was found to have a dramatic influence 
on the phase behavior of the SNEFs, especially when a 
drug with pH-dependent solubility is loaded in the system 
(Date, Nagarsenker, 2007).
Drug
It is important to bear in mind that the therapeutic 
agent of interest can also have a significant impact on 
the various aspects of SETs, such as phase behavior and 
emulsion droplet size. Physiochemical properties of the 
drug, such as log P, pKa, molecular structure and weight, 
presence of ionizable groups and their quantity all have 
considerable impact on the performance of SETs. Date 
and Nagarsenker (2007) observed that the incorporation 
of the drug (Cefpodoxime proxetil) in the SNEFs reduced 
the nano emulsification region when the aqueous phase 
was water. However, as pH of aqueous phase was changed 
to 1.2, the nano-emulsification region increased due to 
pH-dependent solubility of the drug. Furthermore, it was 
also observed that incorporation of drug into the SNEFs 
could increase the nanoemulsion droplet size as compared 
with SNEFs without drug. Similar observations have been 
noted by Wang et al. (2009) in the case of SNEFs of flurbi-
profen. The droplet size of the nano-emulsion was found to 
rise with increasing amounts of drug in the SNEFs. Drugs 
showing surface activity, such as sodium salicylate, ascor-
bic acid and tricyclic amines, may show different behavior 
with an increasing concentration in SNEFs.
In another study, the self nanoemulsification region 
was found to enlarge upon increasing the concentration 
of the drug simvastatin from 10 to 40 mg in the SNEFs. 
These results suggested that simvastatin may have mild 
cosurfactant activity at the oil and water interface due to 
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its amphiphilic nature (Dixit, Nagarsenker, 2008). Owing 
to the acidic nature of self-nanoemulsifying systems, si-
mvastatin prodrug may get converted to simvastatin acid. 
In-silico studies suggested that a high number of rotatable 
bonds in simvastatin acid may interact with the surfactant 
and co-surfactant molecules. Flexibility of a molecule 
helps in forming a close-packed stable interfacial film that 
yields highly stable nano-emulsions. The results imply that 
the properties and amount of the drug have a considerable 
influence on various aspects of SETs.
ROLE OF SELF-EMULSIFYING THERAPEUTIC 
SYSTEMS IN DRUG DELIVERY
Once the formulator succeeds in addressing the chal-
lenges of drug solubility and absorption, the next major 
challenge they face is the delivery of drug in an acceptable 
dosage form. It is an undisputed fact that oral dosage forms 
are the most preferred. Further, lipid formulations offer 
versatility for oral dosage forms as these can be formulated 
into various formulation such as solutions, semi-solids 
and solid forms. Traditionally, lipid-based formulations 
are prepared as liquids and administered orally in either 
soft or hard gelatin capsules. However, there may several 
limitations associated to the delivery of SEFs in hard and 
soft gelatin capsules. These include drug incompatibility, 
instability, drug leakage, precipitation and capsule ageing. 
An alternative method is conversion into a powder form 
which can then be used for formulating tablets, capsules, 
etc. (Nazzal et al., 2002; Newton et al., 2007).
Many lipophilic drugs, e.g., coenzyme Q10, diclofe-
nac, loratadine and cyclosporin A, vitamin E, itroconazole 
etc. have been formulated in SETs. The different drugs, 
their formulations and the excipients used in self-emulsi-
fying therapeutic system are summarized in Table I.
Self-emulsifying tablets (SE tablets)
Incorporation of lipid formulation into a solid 
dosage form combines the advantages of lipid-based 
drug delivery systems with those of solid dosage for-
ms. Attama (2003) formulated a solid self-emulsifying 
formulation using goat fat and tween for the delivery of 
diclofenac. Fatty material was melted and mixed with 
surfactant and the drug incorporated into this mixture. 
This wet mass was poured into plastic molds and cooled 
to form a tablet. During the processing of this formu-
lation it was observed that agitation during fabrication 
of tablets reduced the liquification time, resulting in 
faster emulsification. These results demonstrated that 
different formulation ratios possess varying dissolution 
profiles at constant speed/agitation, and the optimized 
formulation showed good release profiles with accep-
table tablet properties. 
Nazzal and Khan (2006), evaluated the effect of 
some parameters (colloidal silicates-X1, magnesium 
stearate mixing time X2, and compression force X3) 
on coenzyme Q10 (CoQ10) dissolution from tablets of 
eutectic-based SMEFs. The optimized conditions (X1 
= 1.06%, X2 = 2 min, X3 = 1670 kg) were achieved by 
a face centred cubic design. 
In order to significantly reduce the amount of 
solidifying excipients required for transformation of 
SEFs into solid dosage forms, gelled SEFs have been 
developed by Patil (2004). In this study, colloidal si-
licon dioxide (Aerosil 200) was selected as a gelling 
agent for the oil-based systems. Colloidal silicon dio-
xide served a dual purpose: (i) – reducing the amount 
of solidifying excipients required; and (ii) aiding in 
reducing drug release. 
In a clinical study, it was found that SE tablets may 
be of use in reducing adverse effects (Schwarz, 2003). 
The incorporation of indomethacin (or other hydropho-
bic NSAIDs) in SE tablets was found to increase the 
penetration efficacy of the drug through the GI mucosal 
membranes, potentially reducing GI bleeding. The SEF 
in this study composed of glycerol monolaurate and Tylo-
xapol TM (a copolymer of alkyl phenol and formaldehy-
de). The tablets consistently maintained a higher active 
ingredient concentration in blood plasma over the same 
time period compared with a non-emulsifying tablet.
Self-emulsifying powder formulation (SE powder 
formulation)
Arida et al. (2007) formulated an SE powder formu-
lation in order to enhance the dissolution and absorption of 
the poorly water-soluble drug griseofulvin. Capmul GMO-
50, poloxamer and myvacet were used as surfactants and 
co-surfactants. A significant enhancement in dissolution 
(without ultra-micronisation) and bioavailability of grise-
ofulvin was observed.
Balakrishnan et al. (2009) developed a novel solid 
SEF of dexibuprofen using spray drying. Aerosil 200 was 
used as an inert solid carrier. Both in-vitro and in-vivo 
studies were carried out. The optimization of the SEF 
composition was carried out by assessing solubility, prepa-
ration of phase diagram, particle size analysis, drug release 
studies etc. The study showed that Labrafil M 1944 CS, 
Labrafil M 2125, Labrasol, Capryol 90 and Lauroglycol 
FCC could enhance the solubility of CoQ10 and provide 
the desired drug loading.
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Self-emulsifying pellets (SE pellets)
Oral pellets are known to overcome the poor and 
variable GIT absorption of drugs and have shown the 
ability to reduce or eliminate the influence of food on 
bioavailability. Thus, it appears highly appealing to 
combine the advantages of pellets with those of SETs 
by formulating SE pellets. Kang et al. (2004) as part of 
their study to develop a self-emulsifying drug delivery 
system, have reported considerable differences in the 
solubility of simvastatin in a range of surfactants. The 
authors suggest that the properties of surfactants need to 
be considered when selecting them for the formulation 
of SE pellets. 
Franceschinis et al. (2005) developed a new method 
for preparing self-emulsifying pellets by wet granulation 
consisting of a binder solution containing an oil (mono and 
diglycerides), polysorbate 80 and nimesulide as a model 
drug. The oil surfactant mixture was added to water to 
obtain binder solution. The prepared binder solutions were 
sprayed onto the granules (prepared from microcrystalline 
cellulose and lactose) to give pellets. In vivo studies indi-
cated significantly higher bioavailability with the prepared 
pellets in comparison to the corresponding emulsions.
Tuleu (2004) conducted a comparative bioavaila-
bility study of progesterone from SE pellet formulation, 
SE solution, capsule and an aqueous suspension in dogs. 
Complete drug release was seen within 30 min of cap-
sule administration and within 5 min of administration 
of the self-emulsifying system. However, in the case of 
aqueous suspension the drug release was very low (~50% 
of the dose in 60 min). Plasma drug concentration was 
significantly higher when the drug was orally adminis-
tered from self-emulsifying pellets and self-emulsifying 
solution when compared to aqueous suspension at the 
same dose.
Abdalla and Mader (2007) prepared three self-
emulsifying pellet formulations by melting cithrol GMS 
(mono and diglycerides) and solutol HS 15. To this mol-
ten blend, the drug (diazepam) and dry microcrystalline 
cellulose (MCC) were added to obtain a suitable mass 
for extrusion. A dye was incorporated for assessment of 
self-emulsification and spin probe was added to assess the 
release kinetics and microenvironment of pellets. The re-
sults from the release study, with higher load of diazepam 
and lower volume of the dissolution media, indicated that 
the formulation was able to create and maintain a state of 
supersaturation for the poorly water-soluble diazepam. 
Nearly 90% of the drug was released within an hour while 
only 55% was released from the GMS/MCC pellets.
Wang et al. (2010) demonstrated that the extrusion/
spheronization technique is a large-scale production me-
thod for preparing solid SE pellets from the liquid SEF 
to improve oral absorption. SE pellets of a hydrophobic 
drug (nitrendipine) were prepared. Formulation stability 
and solubilisation capacity were noted. The system was 
optimized on the basis of equilibrium solubility, pseudo-
ternary phase diagram and supersaturation studies. The 
liquid SEFs were solidified using adsorbents (porous 
silicon dioxide), MCC and lactose to form fine flowable 
powder. Crospovidone was added to the formulation. The 
AUC of nitrendipine from the SE pellets was two-fold 
greater than the conventional tablets and was comparable 
with the liquid SEFs.
Controlled release self-emulsifying pellets
Serratoni and Newton (2007) observed that the rele-
ase of methyl paraben (MP) and propyl parabens (PP) from 
pellet formulations could be controlled by incorporating 
them into self-emulsifying systems containing water so-
luble plasticiser and talc. Oil and surfactant were mixed 
and added to the damp mass of MCC and lactose mono-
hydrate. Extrusion spheronization of the wet mass was 
carried out. The pellets obtained were initially coated with 
ethyl cellulose and subsequently with an aqueous solution 
of hydroxy propylmethyl cellulose in a fluid bed coater. 
Results obtained from the in vitro study revealed that the 
presence of self-emulsifying system enhanced drug release 
of MP and PP while the film coating considerably reduced 
the drug release from pellets.
Iosio et al. (2008) prepared two types of pellets 
containing vinpocetine (model insoluble drug) where Type 
I pellets contained a self-emulsifying system internally 
and an inert matrix externally, whereas Type II contained 
an inert matrix internally and a self-emulsifying system 
externally. Formulations were prepared in two steps. In the 
first step, the oil-surfactant mixture was added to water to 
form self-emulsifying systems whereas in the next stage 
this mixture was loaded onto MCC and lactose to form 
extrusion-spheronization mass for pellets. Results indica-
ted that Type I pellets released 90% of vinpocetine within 
30 min while the same quantity was released within 20 min 
from Type II pellets. The physical mixture of the excipients 
with drug was able to release around 25% of the drug in 60 
min. Although both types of pellets demonstrated adequate 
morphological and technological characteristics, type II 
pellets showed better drug solubility and in vivo bioavaila-
bility. The above investigations suggest that a solid dosage 
form containing a self-emulsifying system is a promising 
approach for the formulation of drug compounds with poor 
aqueous solubility.
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Self-emulsifying beads (SE beads)
Self-emulsifying beads can be formulated as a 
solid dosage form using smaller amounts of different 
excipients. Patil and Paradkar formulated an isotropic 
formulation of loratadine consisting of Captex 200, 
Cremophore EL and Capmul MCM. The SE mixture 
was loaded onto poly propylene beads (PPB) using the 
solvent evaporation method. Formulations were optimi-
zed for loading efficiency and in vitro drug release by 
evaluating their geometrical features such as bead size 
and pore architecture. Results indicated that the poly 
propylene beads are potential carriers for solidification 
of SE mixture, with sufficiently high SE mixture to PPB 
ratios for the solid form. The results indicated that self-
emulsifying beads can be formulated as a solid dosage 
form with a minimal amount of solidifying agents.
Self-emulsifying sustained-release microspheres
You et al. (2006) prepared solid SE sustained-release 
microspheres of zedoary turmeric oil (oil phase) using 
the quasi-emulsion-solvent-diffusion method involving 
spherical crystallization. The release behaviour of zedoary 
turmeric oil from the formulation was found to be depen-
dent upon the hydroxyl propyl methylcellulose acetate 
succinate to Aerosil 200 ratio. The plasma concentration 
time profiles after oral administration in rabbits showed a 
bioavailability of 135.6% compared with the conventional 
liquid SEFs.
Self-emulsifying implants (SE implants)
Research into SE implants has greatly increased the 
use and application of solid self-emulsifying formulation 
(S-SEF). Carmustine (BCNU) is a chemotherapeutic 
agent used to treat malignant brain tumours. However, 
its effectiveness is hindered by its short half life. In 
order to enhance its stability, the SEF of carmustine 
was formulated using tributyrin, Cremophor RH 40 
(polyoxyl 40 hydrogenated castor oil) and Labrafil 1944 
(polyglycolyzed glyceride). The self-emulsified BCNU 
was fabricated into wafers with a flat and smooth sur-
face by compression moulding. The release profile was 
compared with a wafer implant fabricated using poly 
(d, l-lactide-co-glycolide) acetic acid. It was found that 
SEF increased the in vitro half-life of BCNU to 130 min 
compared with 45 min with intact BCNU. The in vitro 
release of BCNU from self-emulsifying PLGA wafers 
was prolonged up to 7 days and was found to have higher 
in vitro anti-tumor activity (Chae et al., 2005).
Self-microemulsifying formulations
Self-micro emulsifying formulations (SMEFs) have 
attracted great attention recently. In an attempt to combine 
the advantages of SMEFs with those of solid dosage forms 
and overcome the shortcomings of liquid formulations, 
increasing attention has been focused on solid self-(micro) 
emulsifying formulations. The thermotropic stability of 
SMEFs and their high drug loading efficiency make them 
a promising system for low aqueous soluble drugs (Jannin 
et al., 2007). SMEFs are usually placed in soft gelatin 
capsules, but can also be transformed into granules, pel-
lets, powders for dry filled capsules or tablet preparations 
(Nazzal, Khan, 2006; Serratoni, Newton, 2007; Abdalla 
et al., 2008; Tan et al., 2009). The commercial success of 
the SMEF, Neoral® drew greater attention to the develop-
ment of SMEFs. Many poorly water-soluble drugs such as 
acyclovir, atorvastatin, and fenofibrate have been reported 
to offer improved oral bioavailability by SMEFs (Wang et 
al., 2006; Shen, Zhong, 2006; Patel, Vavia, 2007).
Postolache et al. (2002) compared the bioavailability 
of two cyclosporine capsule products with different pharma-
ceutical formulations. Results showed that the test cyclospo-
rine non-SMEFs formulation was not bioequivalent to the 
cyclosporine SMEFs formulation due to a statistically signi-
ficantly lower absorption rate. These authors demonstrated 
that the non-self microemulsifying capsules are not totally 
interchangeable with the self microemulsifying capsules un-
less validated clinical and laboratory conversion protocols 
for each kind of organ transplantation are enforced. 
Catarzi et al. (2008) reported the comparative impact 
of Transcutol and Neusilin® US2 on SMEFs. Results sho-
wed that the Neusilin- formulation resulted in hard tablets 
with a low tablet weight. However, Neusilin® tablets 
had similar disintegration times compare to Aeroperl® 
(Evonik Degussa). The dissolution profile obtained from 
the tablets showed improved profile when compared to 
Glyburide alone. Zvonar et al. (2010) suggested that, 
SMEFs possessing a composition similar to microcapsules 
with Ca-pectinate shell and a drug loaded SMEFs as the 
core phase, would be a potential approach for enhancing 
low permeability and solubility of BCS class II drugs.
Self nanoemulsifying formulations (SNEFs)
The classical lipid nanoparticles that have been 
proposed for drug delivery are composed of solid lipids. A 
distinct advantage of SNEFs over polymeric nanoparticles 
is that the lipid matrix is made from physiologically tole-
rated lipid components, which decreases  potential acute 
and chronic toxicity. 
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Nazzal et al. (2002) developed a SNEF based on the 
eutectic properties of ubiquinone (CoQ10) and also stu-
died the progress of emulsion formation and drug release 
mechanisms by turbidimetry and droplet size analysis. 
Results obtained from study revealed that eutectic-based 
semisolid SEFs can overcome the drawbacks of the tra-
ditional emulsified systems such as low solubility and 
irreversible precipitation of the active drug in the vehicle 
with time.
Cyclosporine lipid nanoparticles (lipospheres) con-
sisting of phospholipids, Span 80, Tween 80, Tricaprin, 
and Cremophor RH 40 were prepared (Bekerman et al., 
2004). The CsA dispersion systems prepared had a particle 
size ranging from 25 nm to 400 nm. Particles with a size 
of 25 nm showed maximum oral bioavailability.
In a study by Nepal et al.(2010),  the surfactant–co-
surfactant blend (Witepsol® H35 and Solutol® HS15) at a 
ratio of 1:4 led to sufficient reduction in free energy of the 
system to resist thermodynamic instability of the nano-
emulsion as well as providing a sufficient mechanical 
barrier to coalescence oil droplets.
Koynova et al. (2010) suggested the use of nano-
sized self-emulsifying lipid vesicles as carriers for the 
inclusion of lipophilic dietary supplements. These were 
proposed as good alternatives to liposomal preparations 
which pose problems in stability, sterilization, and non-
reproducibility between batches.
Supersaturable self-emulsifying formulation
Supersaturation represents a potent technique for 
enhancing absorption by generating and maintaining a 
supersaturated state in the intestine. Such formulations 
contain both a reduced amount of surfactant(s) and a 
polymeric precipitation inhibitor (e.g., water-soluble 
cellulosic polymers, such as HPMC). These maintain a su-
TABLE II - List of selected commercially available lipid-based formulations for oral administration
Active moiety Trade name/
Company
Dosage forms Indication
Cyclosporin A Neoral  
(Novartis)
Soft gelatin capsule, 
50 and 100 mg 
Immuno-suppressant
Sandimmune 
(Novartis)
Soft gelatin capsule, 25, 
50 and 100 mg
Gengraf (Abbott) Hard gelatin capsule
Panimumbioral 
(Panacea Biotec)
Capsule, 50 and 
100 mg
Ritonavir Norvir
(Abbott)
Soft gelatin capsule, 
50 and 100 mg
HIV antiviral
Isotretinoin Accutane 
(Roche)
Soft gelatin capsule, 10, 
20 and 40 mg
Acute promyelocytic 
leukemia
Sanquinavir Fortovase
(Roche)
Soft gelatin capsule, 
200 mg
HIV antiviral
Lopinavir and 
Ritonavir
Kaletra 
(Abbott)
Soft gelatin capsule, 133.33 mg and 
Ritonavir 33.3 mg
HIV-1 antiviral
Tipranavir Aptivus 
(Boehringer Ingelheim)
Soft gelatin capsule, 
250 mg
HIV-1
 Antiviral
Amprenavir Agenerase
(Glaxo Smithkline)
Soft gelatin capsule, 
50 mg
HIV antiviral 
Valproic acid Convulex  
(Pharmacia)
Soft gelatin capsule, 
150, 300, 500 mg
Antiepileptic 
Bexarotene Targretin 
(Ligand)
Soft gelatin capsule, 
75 mg
Antineoplastic 
Calcitriol Rocaltrol 
(Roche)
Soft gelatin capsule , 
0.25, 0.50 mcg
Calcium regulator 
Tretinoin Vesanoid 
(Roche)
Soft gelatin capsule, 
10 mg
Acute promyelocytic 
leukemia
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persaturated state of the drug in the body. As the literature 
suggested, directly supersaturating a system with a drug 
during manufacture adds to the risk of recrystallization of 
the product. Various ways of inhibiting recrystallization 
have been identified. Thermodynamic “freezing” inside a 
polymer is one such option. Under storage conditions, the 
drug is mobilized by thermodynamic changes in the poly-
meric structure. To avoid risk of direct supersaturation, 
several strategies can be employed, for example:
·	 Evaporation of a solvent from the system
·	 Activation of thermodynamically “frozen” drug-
supersaturated islands by hydration.
However, attaining full knowledge of these proces-
ses, especially in a multi- component formulation, requires 
extensive research. Recently, Gao et al. (2008) investigated 
the mechanism responsible for the enhanced intestinal 
absorption of hydrophobic drugs from supersaturable 
SEFs containing HPMC. This effect could be attributed 
to enhanced permeation of drug to the enterocyte brush 
border region through the aqueous pathway by mimicking, 
or equilibrating with, the bile acid /bile acid mixed micelle 
pathway.
MARKETED FORMULATIONS
The successful commercialization of oral lipid- and 
surfactant-based formulations of poorly soluble drugs in 
the market has encouraged researchers to explore the field 
further. Sandimmune®, Sandimmune Neoral®, Norvir® (ri-
tonavir), and Fortovase® (saquinavir) have been formulated 
as SEFs. The Sandimmune® and Sandimmune Neoral® 
formulations of CsA are perhaps the best known examples 
of marketed lipid and surfactant based systems and the 
pharmacokinetic has been studied and reviewed extensively 
(Ritschel, 1996). When diluted with water, these form a 
polydispersed oil-in-water macro/microemulsion.
Another formulation marketed as an amorphous, 
semi-solid dispersion was the hard gelatin capsule of 
ritonavir (Norvir®). However, unexpected precipitation 
of amorphous ritonavir as a less soluble crystalline form 
in the excipient matrix negatively impacted both the drug 
dissolution rate and bioavailability, leading to a tempo-
rary withdrawal of the product from the market in 1998. 
Norvir® was reintroduced in 1999 after reformulation as 
a thermodynamically stable solution containing 100 mg 
of ritonavir solubilized in a self-emulsifying excipient 
delivered in soft gelatin capsules.
Saquinavir was first introduced in 1996 as a solid 
oral dosage form (Invirase®) and subsequently, as a self-
emulsifying lipid-based formulation in a soft gelatin 
capsule (Fortovase®) containing 200 mg of saquinavir. In 
2006, Fortovase® was removed from the market due to lack 
of demand.  Saquinavir is still available as 200 mg and 500 
mg Invirase hard gelatin capsules. Table II lists selected 
commercially available self-emulsifying formulations 
along with their characteristics.
CONCLUSION
The vast majority of new chemical entities and many 
existing drug molecules are poorly soluble. The oral deli-
very of poorly soluble drugs from solid oral dosage form 
continues to encounter significant formulation obstacles, 
such as decreased bioavailability, increased chances of 
food effects, incomplete release and high inter-patient 
variability. Oral SETs are a promising formulation appro-
ach to overcome these problems of poorly water soluble 
drugs. Advanced systems of this type include self nano-
emulsifying (SNEFs) and microemulsifying (SMEFs) 
formulation systems which offer even greater advantages 
in drug delivery owing to the particle size of the dispersed 
phase.  Self-emulsifying formulations can be converted 
to solid oral dosage forms such as granules, pellets and 
tablets with no effects, or only moderate effects, on the in 
vivo behavior of the systems. This characteristic of self-
emulsifying systems is advantageous to formulators and 
is also convenient for patients.
LIST OF ABBREVIATIONS
AUC Area Under Curve
API Active pharmaceutical ingredient
BCNU 1,3-bis (2-chloro ethyl)-1-nitrosourea
BCS Biopharmaceutical classification system 
Cmax Peak Plasma Concentration
CoQ 10 Coenzyme Q 10
CsA Cyclosporine A
GI Gastrointestinal 
HIV Human immuno deficiency virus
HLB Hydrophilic Lipophilic balance  
HPMC Hydroxy propyl methyl cellulose
MCC Micro Crystalline cellulose
NTD Nitrendipine
PEG Polyethylene Glycol 
PGG Polyglycolyzed glycerides
PLGA Poly (d,1-lactide-co-glycolide)
PPB Poly Propylene beads
SE Self Emulsifying
SEFs Self Emulsifying formulations
SETS Self Emulsifying therapeutic systems
SMEDDS Self Microemulsifying drug delivery system
SMEFs  Self-Micro emulsifying formulations 
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SNEFs Self nanoemulsifying Formulations
S-SEDDS Solid self-emulsifying drug delivery system
S-SEFs  Super Saturable Self emulsifying formulations
Tmax Time to reach peak plasma concentration
TPGS  d-alpha tocopheryl polyethylene glycol 1000 
 succinate 
ZTO Zedoary Turmeric Oil
NSAID Nonsteroidal anti-inflammatory Drug
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